Erasca (ERAS) Non Operating Income (2020 - 2026)
Erasca's (ERAS) quarterly Non Operating Income came in at $4.5 million in Q1 2026, down 4.14% YoY from $4.7 million in Q1 2025, and up 27.31% on a QoQ basis from $3.5 million in Q4 2025.
Analysis
Erasca (ERAS) Non Operating Income (2020 - 2026) Analysis & Trends
Erasca (ERAS) has 7 years of Non Operating Income data on file, last reported at $4.5 million in Q1 2026.
- Quarterly Non Operating Income fell 4.14% year-over-year to $4.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.2 million (down 14.73% YoY) and the FY2025 annual result came in at $16.4 million, down 8.8% from the prior year.
- Non Operating Income grew to $4.5 million in Q1 2026, from $3.5 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $5.9 million in Q3 2024 to a low of $47000.0 in Q1 2022.
- A 5-year average of $3.5 million and a median of $3.9 million in 2025 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2023 — Non Operating Income jumped 8040.43% — and 2025, when it sank 32.97%.
- Tracing ERAS's Non Operating Income over 5 years: stood at $2.6 million in 2022, then jumped by 59.14% to $4.2 million in 2023, then decreased by 16.57% to $3.5 million in 2024, then rose by 0.92% to $3.5 million in 2025, then gained by 27.31% to $4.5 million in 2026.
- The last three Non Operating Income figures came in at $4.5 million (Q1 2026), $3.5 million (Q4 2025), and $3.9 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -139.24 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | -51.63 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | - |
| 10 | Erasca | 5.02 Bn | 5.02 Bn | - | 3.54 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.54 Mn |
| Mar 31, 2026 | 4.47 Mn |
| Dec 31, 2025 | 3.51 Mn |
| Sep 30, 2025 | 3.93 Mn |
| Jun 30, 2025 | 4.25 Mn |
| Mar 31, 2025 | 4.66 Mn |
| Dec 31, 2024 | 3.48 Mn |
| Sep 30, 2024 | 6.04 Mn |
| Jun 30, 2024 | 4.58 Mn |
| Mar 31, 2024 | 3.83 Mn |
| Dec 31, 2023 | 4.17 Mn |
| Sep 30, 2023 | 4.30 Mn |
| Jun 30, 2023 | 4.19 Mn |
| Mar 31, 2023 | 3.83 Mn |
| Dec 31, 2022 | 2.83 Mn |
| Sep 30, 2022 | 1.47 Mn |
| Jun 30, 2022 | 297,000.00 |
| Mar 31, 2022 | 47,000.00 |
| Dec 31, 2021 | 584,000.00 |
| Sep 30, 2021 | -25,000.00 |